These findings suggest that simufilam treatment in a TSC mouse model prevented the worsening of seizure activity in a dose-dependent manner and supports clinical investigation of simufilam as a potential therapeutic intervention for seizures in TSC.
Stansley et al. (Tue,) studied this question.